Physician profile
Roger Boatwright
NPI 1386628071
$12,573.08
in general payments reported to CMS, 2019-2025
51 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $1,479 · 2021: $1,923 · 2022: $1,951 · 2023: $1,825 · 2024: $2,005 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,430.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,773.64 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $1,097.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,079.58 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,031.99 | 2019-2025 | |
| Lilly USA, LLC | $964.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $615.21 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $516.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.13 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.98 | 2019-2025 | Xifaxan |
| Amgen INC. | $372.86 | 2019-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $371.84 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $341.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $313.91 | 2020-2025 | Spravato |
| Amarin Pharma, INC. | $244.98 | 2019-2021 | |
| Abbott Laboratories | $230.40 | 2019-2024 | Proclaim, Freestyle Libre 3 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $222.38 | 2021-2025 | |
| Dexcom, INC. | $205.31 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $202.10 | 2020-2025 | Nexletol |
| Allergan, INC. | $193.46 | 2019-2020 | |
| Exact Sciences Corporation | $158.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $151.84 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $132.06 | 2020-2021 | |
| Insulet Corporation | $114.79 | 2024-2025 | Omnipod |
| Nestle Healthcare Nutrition INC. | $106.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $100.39 | 2020-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $97.18 | 2023-2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $95.55 | 2019-2022 | |
| Daiichi Sankyo INC. | $89.16 | 2019-2024 | Injectafer |
| Axsome Therapeutics, INC. | $86.05 | 2022-2025 | Auvelity, Symbravo |
| Corcept Therapeutics | $85.82 | 2021-2022 | |
| Astellas Pharma US INC | $83.60 | 2021-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $81.28 | 2022-2024 | Camzyos, Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.51 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $63.10 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Xeris Pharmaceuticals, INC. | $57.76 | 2023-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $57.73 | 2023-2025 | Voquezna |
| Antares Pharma, INC. | $47.29 | 2022-2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.76 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $36.89 | 2019 | |
| Biogen, INC. | $31.66 | 2021 | |
| Hikma Pharmaceuticals USA | $29.20 | 2023-2024 | Ryaltris |
| Scilex Pharmaceuticals INC. | $22.21 | 2023 | Ztlido |
| Azurity Pharmaceuticals, INC. | $19.17 | 2024 | |
| Nabriva Therapeutics, Plc | $18.81 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.28 | 2022 | |
| Mylan Specialty L.P. | $16.17 | 2020 | |
| Shield Therapeutics INC | $15.52 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.31 | 2021 | |
| Sanofi Pasteur INC. | $13.18 | 2019 | |
| Boston Scientific Corporation | $13.07 | 2019 | |
| Currax Pharmaceuticals LLC | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Boatwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.